Niacinamide combinations represent another approach to optimizing results without switching the base medication
Technically yes, but most people find their tolerance drops significantly
[1] [22] Both formulations carry a boxed warning regarding thyroid C-cell tumors observed in rodent studies, though the clinical relevance to humans remains uncertain
In August, drug manufacturer Eli Lilly began sending cease-and-desist letters to telehealth companies, wellness centers and medical spas selling compounded versions of Zepbound and Mounjaro, according to Reuters
Studies show that weight regain begins within days of stopping GLP-1 therapy, with patients returning to baseline eating patterns and losing 50% or more of their weight loss gains within a year
At this point, switching to a dual or triple agonist like tirzepatide may provide additional benefit